Heron Therapeutics stock trades at penny level as biotech focuses on pain and oncology pipeline

Published on 09/03/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Heron Therapeutics stock remains at a low market-cap level while the biotech company advances its pain management and oncology drugs for ambulatory surgical settings and cancer patients.

HRTX, US4277461020, Illustration mit AI erstellt.

Heron Therapeutics stock (ISIN US4277461020) continues to trade at a very low price level, with market data from September 2, 2026 showing a quotation of around USD 0.31 and a market capitalization of about USD 59.4 million for the biotechnology company.

Small-cap biotech with limited market value

According to market information compiled by a major US financial portal as of September 2, 2026, Heron Therapeutics, Inc. is valued at approximately USD 59.4 million in market capitalization, reflecting investor caution toward smaller biotechnology stocks.

The same data source lists the share price of Heron Therapeutics at USD 0.3129 on September 2, 2026, which places the company firmly in penny-stock territory and highlights how far the stock has fallen from historical levels in previous years.

Revenue base and recent operating performance

In recent reporting periods within the last two fiscal years, Heron Therapeutics has generated annual revenue in the lower hundreds of millions of dollars from its portfolio of pain management and oncology supportive-care products, with typical figures for the most recently reported year indicating revenue above USD 100 million.

Quarterly results over the last four quarters show that Heron Therapeutics remains loss-making on a net basis but has managed to narrow operating losses compared with earlier periods, with management emphasizing expense discipline and a focus on commercial execution for its marketed therapies.

Go deeper

More on Heron Therapeutics stock

Further details on the company and its stock history are available in the dedicated overview for the ISIN US4277461020.

Heron Therapeutics overview Investor Relations

Pain management products for ambulatory surgery

Heron Therapeutics focuses its commercial activities primarily on pain management solutions for patients undergoing ambulatory surgeries, where the goal is to reduce postoperative pain and facilitate same-day discharge without relying heavily on opioid medication.

The company has developed and marketed injectable formulations designed to provide extended pain relief over several days, supporting hospital outpatient departments and ambulatory surgery centers that seek to reduce opioid exposure while maintaining patient comfort.

Stock price snapshot and investor view

Market data on September 2, 2026 indicate that Heron Therapeutics stock closed around USD 0.31 in regular US trading, underscoring the modest valuation level and the high sensitivity of the share price to clinical, regulatory and commercial developments.